557,483 Shares in AstraZeneca Plc $AZN Purchased by William Blair Investment Management LLC

William Blair Investment Management LLC bought a new position in shares of AstraZeneca Plc (NYSE:AZN – Free Report) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 557,483 shares of the company’s stock, valued at approximately $90,809,000.

A number of other institutional investors have also made changes to their positions in the business. Allworth Financial LP raised its stake in AstraZeneca by 313.0% in the 3rd quarter. Allworth Financial LP now owns 33,413 shares of the company’s stock valued at $5,395,000 after acquiring an additional 25,322 shares during the period. GKV Capital Management Co. Inc. lifted its holdings in AstraZeneca by 14.8% during the 3rd quarter. GKV Capital Management Co. Inc. now owns 12,905 shares of the company’s stock valued at $2,100,000 after purchasing an additional 1,660 shares during the last quarter. Fisher Asset Management LLC lifted its holdings in AstraZeneca by 3.2% during the 3rd quarter. Fisher Asset Management LLC now owns 11,501,748 shares of the company’s stock valued at $1,857,187,000 after purchasing an additional 355,456 shares during the last quarter. Legacy Trust bought a new position in AstraZeneca during the third quarter worth $254,000. Finally, Russell Investments Group Ltd. boosted its position in AstraZeneca by 0.9% during the third quarter. Russell Investments Group Ltd. now owns 2,052,004 shares of the company’s stock worth $334,070,000 after purchasing an additional 18,417 shares during the period. 20.35% of the stock is owned by institutional investors and hedge funds.

AstraZeneca Stock Performance

AZN opened at $184.66 on Monday. The business has a fifty day simple moving average of $168.82 and a 200 day simple moving average of $180.20. The company has a market capitalization of $286.40 billion, a PE ratio of 26.12, a price-to-earnings-growth ratio of 1.43 and a beta of 0.24. AstraZeneca Plc has a 1 year low of $153.41 and a 1 year high of $212.71. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.01 and a quick ratio of 0.79.

AstraZeneca (NYSE:AZN – Get Free Report) last posted its earnings results on Saturday, October 31st. The company reported $2.79 earnings per share for the quarter, topping analysts’ consensus estimates of $2.60 by $0.19. The company had revenue of $16.21 billion during the quarter, compared to the consensus estimate of $16 billion. AstraZeneca had a return on equity of 31.85% and a net margin of 17.68%. The company’s revenue was up 6.5% on a year-over-year basis. During the same quarter last year, the firm earned $2.38 earnings per share. Research analysts expect that AstraZeneca Plc will post 10.22 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Royal Bank Of Canada assumed coverage on shares of AstraZeneca in a report on Tuesday, September 8th. They issued an “outperform” rating on the stock. Wall Street Zen upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a research note on Saturday, October 31st. Weiss Ratings upgraded shares of AstraZeneca from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Monday, October 26th. Deutsche Bank raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Tuesday, September 15th. Finally, CICC Research began coverage on shares of AstraZeneca in a research note on Sunday, August 23rd. They issued an “outperform” rating and a $198.00 price target on the stock. Sixteen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $206.67.

Read Our Latest Stock Report on AstraZeneca

About AstraZeneca

(Free Report)

AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries. AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.

Featured Articles

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca Plc (NYSE:AZN – Free Report).

Institutional Ownership by Quarter for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.